Core Insights - Theriva Biologics has successfully engaged with the FDA, allowing the advancement into a proposed Phase 3 clinical trial for VCN-01 in combination with gemcitabine/nab-paclitaxel for treating metastatic pancreatic ductal adenocarcinoma (PDAC) [1][4] Group 1: Clinical Trial Design and Feedback - The FDA has provided general agreement on Theriva's proposed design for the Phase 3 clinical trial, which is aligned with the successful VIRAGE Phase 2 trial that demonstrated improved overall survival (OS), progression-free survival (PFS), and Duration of Response (DoR) in patients receiving VCN-01 with standard-of-care chemotherapy [2] - The Phase 3 trial will include repeat dosing of VCN-01 and an adaptive design to optimize timelines and outcomes, based on the positive results from the Phase 2 trial [2][4] - The FDA has indicated that a potential biologics licensing application (BLA) for VCN-01 could be supported by the proposed Phase 3 trial, which will compare VCN-01 plus chemotherapy to chemotherapy plus placebo [3] Group 2: Company Strategy and Future Plans - The combined feedback from the FDA and EMA allows the company to finalize the protocol for the pivotal Phase 3 clinical trial and pursue strategic funding opportunities [1][4] - The CEO of Theriva Biologics expressed optimism that administering multiple macrocycles of VCN-01 alongside chemotherapy may further enhance patient outcomes [4] - The company aims to deliver a novel treatment option for patients with difficult-to-treat solid tumors, leveraging the insights gained from regulatory feedback [4] Group 3: Background on PDAC and VCN-01 - Pancreatic ductal adenocarcinoma (PDAC) accounts for over 90% of pancreatic tumors and is often diagnosed at advanced stages, making treatment challenging [5] - VCN-01 is an oncolytic adenovirus designed to selectively replicate within tumor cells, degrade tumor stroma, and enhance the efficacy of co-administered chemotherapy [6][7] - The therapeutic approach of VCN-01 aims to improve access to chemotherapy and stimulate an immune response against the tumor [7]

Oncology Focus and Product Development - The company transitioned its strategic focus to oncology following the acquisition of Theriva Biologics in March 2022, emphasizing the development of VCN's oncolytic adenovirus platform for cancer treatment [21]. - VCN-01, the lead product candidate, is a clinical-stage oncolytic human adenovirus currently evaluated in a Phase 2b study for pancreatic cancer and various Phase 1 studies for other solid tumors, with 142 patients treated to date [38]. - The five-year overall survival rate for pancreatic ductal adenocarcinoma (PDAC) is less than 10%, highlighting a significant unmet medical need in this area [40]. - VCN-01 has received Orphan Drug designation from the FDA for pancreatic cancer treatment in June 2023 and Fast Track designation in May 2024, facilitating its development [44][45]. - The company is exploring value creation options for its SYN-004 asset, including out-licensing or partnering, as part of its strategic transformation into an oncology-focused company [24]. - The Rasayana License Agreement allows Rasayana Therapeutics to develop and commercialize SYN-020, relieving the company from further investment in this asset and enabling a focus on oncology [23]. - The company’s oncology platform utilizes oncolytic virotherapy, which exploits the ability of viruses to selectively kill tumor cells and stimulate an anti-tumor immune response [31]. - The current market opportunity for PDAC is significant, as it is projected to become the second leading cause of cancer-related deaths in the U.S. by 2030 [40]. - The company’s product pipeline includes additional candidates like SYN-006 and SYN-007, aimed at addressing gastrointestinal diseases, although the primary focus has shifted to oncology [30]. Clinical Trial Results and Efficacy - The Phase 1 trial of intravenous VCN-01 demonstrated an overall response rate (ORR) of 50% for patients with pancreatic adenocarcinoma in both Part II and Part III of the study [48]. - Median progression-free survival (PFS) for patients in Part III was reported at 6.7 months, while median overall survival (OS) was 13.5 months, with 66.7% of patients surviving more than 12 months [48]. - The Phase 2b VIRAGE trial initiated in January 2023 aimed to evaluate VCN-01 in combination with standard-of-care chemotherapy for newly-diagnosed metastatic pancreatic ductal adenocarcinoma [49]. - As of September 23, 2024, the target enrollment of 92 evaluable patients in the VIRAGE trial was achieved, with 36 patients receiving their second doses of VCN-01 [50]. - The Independent Data Monitoring Committee (IDMC) confirmed that VCN-01 was well tolerated, with no new safety concerns raised during the trial [51]. - Positive topline outcomes from the VIRAGE trial indicated that patients receiving two doses of VCN-01 had a median OS of 14.8 months compared to 11.6 months for those receiving standard chemotherapy alone [59]. - The trial also showed improved PFS for the VCN-01 group at 11.2 months versus 7.4 months for the control group [63]. - The FDA granted Fast Track Designation to VCN-01 in combination with gemcitabine and nab-paclitaxel to improve PFS and OS in metastatic pancreatic adenocarcinoma patients [53]. - The FDA advised a stand-alone Phase 3 study design for VCN-01, indicating that additional standard-of-care chemotherapy was not necessary for the study [54]. - The European Medicines Agency (EMA) provided guidance that positive results from a Phase 3 study could support a marketing authorization application for VCN-01 in metastatic pancreatic adenocarcinoma [55]. - The company received additional Scientific Advice from the CHMP of the EMA regarding the Phase 3 trial design for VCN-01 in combination with gemcitabine/nab-paclitaxel for metastatic PDAC, with a focus on a compelling benefit-risk ratio [65]. - The Phase 1 trial of VCN-01 in retinoblastoma patients showed that the treatment was well tolerated, with no systemic toxicities and a significant ocular preservation rate [75]. - The FDA granted Orphan Drug designation to VCN-01 for retinoblastoma treatment in February 2022, and Rare Pediatric Drug Designation in July 2024, indicating the drug's potential for serious pediatric conditions [69][73]. - In the Phase 1 trial combining VCN-01 with durvalumab, the overall survival (OS) was 10.4 months for the concomitant group and 15.5 months for the sequential group at the 3.3×10^12 vp dose [79]. - The study presented at ESMO 2023 indicated that 61.1% of patients were alive after 12 months, demonstrating the potential effectiveness of VCN-01 in advanced cancer treatments [79]. Financial and Licensing Agreements - The company is obligated to pay €320,265 (approximately $334,000) to Hospital Sant Joan de Déu for the exclusive worldwide technology license related to VCN-01 for pediatric retinoblastoma [71]. - An upfront payment of $300,000 was received from Rasayana under the Rasayana License Agreement, with potential development milestone payments of up to $16.0 million and sales milestone payments of up to $22.0 million [124]. - The Rasayana License Agreement grants Rasayana an exclusive worldwide license for SYN-020, with an upfront payment of $300,000 and potential milestone payments totaling up to $38 million [146]. - The acquisition of VCN Biosciences was completed for a total consideration of $4.7 million and 2,639,530 shares of common stock, representing 19.99% of the outstanding shares [131]. - Milestone payments related to the VCN-01 program include $3 million for US IND Safe to Proceed for PDAC, $3.25 million for the first patient dosed in PDAC, and $12 million upon BLA approval for PDAC [132]. - The company has over 135 U.S. and foreign patents and over 50 patents pending, indicating a robust intellectual property portfolio [126]. - The company expects to incur no material expenditures for further research and development of SYN-020 following the Rasayana License Agreement [123]. - The company relies on a combination of patent, copyright, trademark, and trade secret laws to protect its intellectual property rights [125]. Manufacturing and Regulatory Compliance - Manufacturing of VCN-01 and other oncolytic viruses is conducted through third-party CDMOs, with no in-house manufacturing facilities [150]. - The FDA regulates all aspects of product development, including formulation, manufacturing, and labeling, which imposes significant compliance costs [156]. - The company has faced delays in manufacturing due to COVID-19 related supply chain issues, impacting clinical trials [152]. - The company must ensure compliance with good manufacturing practices (GMPs) and submit results to the FDA as part of the NDA or BLA for marketing approval [170]. - The approval of new medicinal products in the European Union can be obtained through three processes: mutual recognition, centralized, and decentralized procedures [194]. - The centralized procedure is mandatory for products developed by biotechnological processes and optional for new active substances, allowing for a single marketing authorization valid throughout the EU [196]. - The mutual recognition procedure allows for marketing authorizations granted in one EU member state to be recognized by others within 55 days, with a resolution process for any objections [195]. - Post-marketing requirements include ongoing regulation by the FDA and other authorities, which involve monitoring, recordkeeping, and compliance with advertising standards [198]. Market Landscape and Competition - The pharmaceutical industry faces intense competition from well-established companies with greater resources, including strategic collaborations that enhance their R&D capabilities [212]. - Only three oncolytic virus (OV) products have been approved globally, highlighting the competitive landscape in oncology product development [215]. - More than 60 companies are pursuing clinical development of various forms of oncolytic virus (OV) products [216]. - Companies targeting pancreatic cancer or PDAC with OV products include Akamis Bio Ltd, Boehringer Ingelheim GmbH, and Oncolytics Biotech [218]. - Seneca Therapeutics Inc. and Shanghai Sunway Biotech Co., Ltd. have identified retinoblastoma as a potential target indication for OV products [220].

Financial Position - Theriva Biologics reported cash and cash equivalents of $13.1 million as of December 31, 2025, increasing to $15.2 million as of February 26, 2026, providing a cash runway into Q1 2027[1][8] - Total assets increased to $38,239 million in 2025 from $35,352 million in 2024, representing a growth of 8.0%[16] - Current liabilities rose to $10,014 million in 2025, up from $7,585 million in 2024, an increase of 32.0%[16] - Total stockholders' equity decreased to $15,383 million in 2025 from $19,067 million in 2024, a decline of 19.0%[16] Expenses - General and administrative expenses rose to $15.4 million for the year ended December 31, 2025, a 109% increase from $7.4 million in 2024, primarily due to a $9.0 million contingent consideration adjustment[5] - Research and development expenses decreased by 28% to $8.6 million for the year ended December 31, 2025, down from $12.0 million in 2024, attributed to lower clinical trial expenses[6] - General and administrative expenses increased significantly to $15,447 million in 2025 from $7,396 million in 2024, an increase of 109.0%[18] - Research and development expenses decreased to $8,604 million in 2025 from $12,031 million in 2024, a reduction of 28.0%[18] - Total operating costs and expenses decreased to $24,051 million in 2025 from $26,346 million in 2024, a decline of 8.7%[18] Clinical Development - Theriva Biologics licensed SYN-020 to Rasayana Therapeutics, with potential milestones of up to $38 million plus royalties on commercial sales[1][2] - The company plans an End-of-Phase 2 meeting with the FDA in the first half of 2026 to finalize the design for a pivotal multinational Phase 3 trial in pancreatic ductal adenocarcinoma (PDAC)[2][3] - VCN-01 received positive scientific advice from the EMA for a Phase 3 trial in PDAC, including agreement on sample size and primary endpoint of overall survival[3] - SYN-020 is poised to enter Phase 2 clinical testing, with Rasayana assuming responsibility for future clinical development and commercialization costs[7][11] - Theriva Biologics aims to engage in further discussions with the FDA and EMA in 2026 to refine the design of a potential Phase 2/3 trial for retinoblastoma[7] - The company has administered VCN-01 to 142 patients in clinical trials across various cancers, demonstrating its potential in treating difficult-to-treat tumors[10] Loss and Shareholder Impact - Net loss attributable to common stockholders for 2025 was $25,249 million, compared to $25,653 million in 2024, showing a slight improvement of 1.6%[18] - The net loss per share for 2025 was $2.08, compared to $19.03 in 2024, indicating a substantial improvement in loss per share[18] - Total comprehensive loss for 2025 was $21,806 million, down from $26,863 million in 2024, reflecting a decrease of 18.8%[18] - The weighted average number of shares outstanding during the period increased to 12,140,697 in 2025 from 1,348,126 in 2024, a significant rise of 800.0%[18]

Core Insights - Theriva Biologics, Inc. is advancing its clinical development of VCN-01 for pancreatic ductal adenocarcinoma (PDAC) and retinoblastoma, with plans for pivotal trials in 2026 [2][5] Financial Results - For the year ended December 31, 2025, general and administrative expenses rose to $15.4 million, a 109% increase from $7.4 million in 2024, primarily due to a contingent consideration adjustment of $9.0 million related to the VIRAGE Phase 2b clinical trial [7] - Research and development expenses decreased to $8.6 million in 2025 from $12.0 million in 2024, a 28% reduction attributed to lower clinical trial costs [8] - Cash and cash equivalents were $13.1 million as of December 31, 2025, up from $11.6 million in 2024, with a current cash position of approximately $15.2 million as of February 26, 2026, expected to fund operations into Q1 2027 [9] Licensing and Partnerships - Theriva licensed SYN-020 to Rasayana Therapeutics for $300,000 upfront and potential milestones of up to $38 million, including royalties on commercial sales [3][4] - The company is engaging in partnership discussions for additional innovative drug candidates in its portfolio [2] Clinical Development Updates - The European Medicines Agency (EMA) provided positive feedback on the Phase 3 trial design for VCN-01 in combination with gemcitabine/nab-paclitaxel for metastatic PDAC [5] - An End-of-Phase 2 meeting with the FDA is scheduled for the first half of 2026 to finalize the design for a multinational pivotal Phase 3 trial in PDAC [5] - VCN-01 has received Orphan Drug and Rare Pediatric Disease designations for retinoblastoma, with further discussions planned with the FDA and EMA in 2026 [5] Product Information - VCN-01 is an oncolytic adenovirus designed to selectively replicate within tumor cells and degrade tumor stroma, enhancing the efficacy of co-administered therapies [11] - SYN-020 is a recombinant bovine intestinal alkaline phosphatase aimed at addressing metabolic and inflammatory disorders, now poised to enter Phase 2 clinical testing [12]

Core Insights - The biotech industry experienced significant developments this week, including FDA approvals, clinical trial results, and licensing agreements, indicating a dynamic landscape for investment opportunities and advancements in healthcare [1]. FDA Approvals & Rejections - NRx Pharmaceuticals is on track for FDA approval of NRX-100, with existing clinical data and real-world evidence from over 65,000 patients potentially supporting a New Drug Application (NDA) under Fast Track Designation [2][3]. - Kane Biotech received FDA clearance for its Revyve Antimicrobial Skin and Wound Cleanser, which targets wound bacteria and biofilms, with plans for manufacturing scale-up in 2026 [4][5]. - Johnson & Johnson's RYBREVANT FASPRO received FDA approval for a simplified monthly dosing schedule, enhancing treatment options for patients with advanced non-small cell lung cancer [6][7]. - Spruce Biosciences reported positive feedback from FDA Type B meetings for its enzyme replacement therapy for Sanfilippo syndrome type B, with a targeted BLA filing in Q4 2026 [8][9]. - Moderna's seasonal influenza vaccine submission (mRNA-1010) is under FDA review, with a PDUFA date set for August 5, 2026, aiming for availability in the 2026/2027 flu season [10][11]. - Disc Medicine received a Complete Response Letter (CRL) for its NDA for Biopertin in erythropoietic protoporphyria, citing insufficient correlation with sunlight exposure endpoints [13][14]. - AbbVie and Genentech's combination regimen of VENCLEXTA and Acalabrutinib for chronic lymphocytic leukemia (CLL) received FDA approval, showing a 35% reduction in disease progression risk compared to standard treatment [15][16]. Deals - Theriva Biologics entered an exclusive licensing agreement with Rasayana Therapeutics for SYN-020, receiving a $3 million upfront payment and potential milestone payments totaling up to $38 million [17][18]. - Sensei Biotherapeutics acquired Faeth Therapeutics, expanding its oncology portfolio with the investigational asset PIKTOR, and announced a concurrent private placement of $200 million to advance clinical milestones [19][20]. Clinical Trials - Breakthroughs - Eli Lilly's Taltz and Zepbound combination therapy showed positive results in a Phase 3 trial for plaque psoriasis and obesity, achieving superior outcomes compared to Taltz alone [21][22]. - Zealand Pharma reported positive Phase 1a results for ZP9830, a Kv1.3 channel blocker, demonstrating safety and tolerability in healthy volunteers [23][24]. - Novartis' Remibrutinib met primary endpoints in a Phase 3 trial for chronic inducible urticaria, showing significant response rates compared to placebo [26][27]. - Ocular Therapeutix's AXPAXLI demonstrated superiority over aflibercept in a Phase 3 trial for wet age-related macular degeneration, although stock prices fell due to investor disappointment [28][29]. - Rallybio's RLYB116 Phase 1 study showed promising results for immune platelet transfusion refractoriness, with plans for a Phase 2 trial in 2026 [31][32]. - Teva and Sanofi's Duvakitug Phase 2b trial demonstrated durable efficacy in ulcerative colitis and Crohn's disease, reinforcing the rationale for ongoing Phase 3 programs [35][36]. - Genentech's Gazyva met primary endpoints in a Phase III study for primary membranous nephropathy, showing significant remission rates compared to tacrolimus [38][39].

Core Insights - Theriva Biologics has out-licensed SYN-020 to Rasayana Therapeutics, receiving an upfront payment of $300,000 and is eligible for up to $38 million in development, regulatory, and sales milestones along with tiered single-digit royalties on net product sales [1][4] Company Overview - Theriva Biologics is a diversified clinical-stage company focused on developing therapeutics for cancer and related diseases, with a lead program in pancreatic cancer, VCN-01 [5] - The company is advancing a new oncolytic adenovirus platform aimed at improving cancer treatment outcomes [5] Product Details - SYN-020 is a recombinant bovine intestinal alkaline phosphatase designed to reduce fat absorption, intestinal inflammation, and promote a healthy microbiome, with potential applications in multiple metabolic and inflammatory disorders [2] - SYN-020 has shown good tolerability in Phase 1 clinical studies and is set to enter Phase 2 clinical testing with Rasayana [2] Partnership Insights - Rasayana Therapeutics will assume all responsibilities and costs for the development and commercialization of SYN-020, leveraging their expertise in gut-targeted therapies [1][4] - The partnership is expected to enhance the development of SYN-020, with Rasayana's leadership expressing strong confidence in the product's therapeutic potential [3]

Core Insights - Theriva Biologics is presenting safety and clinical outcomes from a Phase 1 study of VCN-01 in refractory retinoblastoma patients at the APAO Congress in Hong Kong on February 7, 2026 [1] - Preclinical data indicates that the combination of topotecan and VCN-01 may enhance antitumor activity in difficult-to-treat cases of retinoblastoma [1] Company Overview - Theriva Biologics is a clinical-stage company focused on developing therapeutics for cancer and related diseases, addressing areas of high unmet medical need [8] - The company’s lead candidate, VCN-01, is an oncolytic adenovirus designed to selectively replicate within tumor cells and degrade tumor stroma, enhancing the efficacy of co-administered therapies [4][8] Clinical Study Details - The Phase 1 clinical study (NCT03284268) evaluates the safety and tolerability of two intravitreal injections of VCN-01 in pediatric patients with intraocular retinoblastoma [1] - The study aims to provide an alternative to enucleation for patients who have not responded to other forms of chemotherapy [3] Preclinical Findings - Preclinical data will be presented that shows the synergistic effects of combining topotecan with VCN-01, potentially improving treatment outcomes for patients with vitreous seeds [1][3] Regulatory Designations - VCN-01 has received Orphan Drug and Rare Pediatric Disease designations from the FDA for the treatment of retinoblastoma, indicating its potential significance in addressing this rare cancer [3][4] Retinoblastoma Overview - Retinoblastoma is the most common type of eye cancer in children, occurring in approximately 1 in 14,000 to 1 in 18,000 live newborns, with a significant incidence in the pediatric population [7] - The average age of diagnosis is around 2 years, and effective treatment remains a challenge, particularly in low-resource countries [7]

Core Insights - Theriva Biologics has received scientific advice from the EMA regarding the Phase 3 clinical trial design for VCN-01 in combination with gemcitabine/nab-paclitaxel for treating metastatic PDAC [1][3] - The company plans to hold an End-of-Phase 2 meeting with the FDA in H1 2026 to finalize the design of a pivotal multinational Phase 3 clinical trial [1][4] - Theriva's cash runway extends until Q1 2027, allowing for the completion of regulatory activities and protocol development for VCN-01 trials [1][4] Clinical Trial Developments - The Phase 2b clinical trial (VIRAGE) showed that patients receiving VCN-01 with standard chemotherapy had improved overall survival and progression-free survival compared to those receiving chemotherapy alone [2] - The CHMP supports a single, high-quality, double-blinded, randomized, placebo-controlled Phase 3 trial if it demonstrates a compelling benefit-risk ratio [3] - The proposed trial design includes adaptive elements, primary endpoint of overall survival, and secondary endpoints such as progression-free survival and duration of response [3] Regulatory and Financial Outlook - The company is encouraged by the EMA's agreement on the dosing regimen for VCN-01, which may enhance survival outcomes [4] - Theriva had $15.5 million in cash and equivalents as of November 10, 2025, providing sufficient funds to support ongoing regulatory interactions and potential partnerships [4] - The company aims to seek regulatory advice for a potential Phase 2/3 trial of VCN-01 in retinoblastoma in 2026 [4]

Oncology Focus - The company transitioned its strategic focus to oncology following the acquisition of Theriva Biologics in March 2022, developing the oncolytic adenovirus platform for cancer treatment [122]. - The lead product candidate, VCN-01, is currently in a Phase 2b clinical study for pancreatic cancer and has been used in Phase 1 studies for retinoblastoma and other solid tumors [122]. - The VIRAGE Phase 2b trial for metastatic pancreatic cancer involved 112 patients, comparing standard chemotherapy with and without VCN-01 [135]. - Patients receiving VCN-01 + GA showed improved overall survival (OS) of 14.8 months compared to 11.6 months for GA alone, with a hazard ratio (HR) of 0.44 (P=0.046) [136]. - The Phase 2b VIRAGE trial achieved target enrollment of 92 evaluable patients, with 36 patients receiving their second doses of intravenous VCN-01, which were well tolerated [146]. - VCN-01 has been administered to 142 patients across multiple Phase 1 clinical trials and the Phase 2b VIRAGE trial, targeting various cancers including pancreatic cancer and retinoblastoma [142]. - The FDA granted Fast Track Designation to VCN-01 in combination with gemcitabine and nab-paclitaxel to improve progression-free survival and overall survival in patients with metastatic pancreatic adenocarcinoma [149]. - The Independent Data Monitoring Committee found that VCN-01 was well tolerated in combination with standard-of-care chemotherapy, with adverse events consistent with prior clinical trials [153]. - The company received Rare Pediatric Drug Designation for VCN-01 for the treatment of retinoblastoma, which may lead to a Priority Review Voucher if approved by September 30, 2026 [160]. - The European Medicines Agency granted Orphan Medicinal Product Designation to VCN-01 for the treatment of retinoblastoma [161]. - VCN-01 demonstrated enhanced anti-tumor effects in human pancreatic cancer xenograft-bearing mice when combined with liposomal irinotecan [148]. - The Phase 2b trial of VCN-01 in combination with standard-of-care chemotherapy is being conducted at approximately 17 sites in the US and EU [145]. - The company plans to conduct a stand-alone Phase 3 study of VCN-01 with gemcitabine/nab-paclitaxel based on FDA guidance [151]. - The Phase 1 trial of VCN-01 combined with durvalumab enrolled 20 patients, with a median of 4 prior lines of therapy, showing promising results in both concomitant and sequential administration schedules [164]. - In the concomitant schedule, overall survival (OS) was 10.4 months, while in the sequential schedule, OS was 15.5 months at a dose of 3.3×10^12 viral particles (vp) and 17.3 months at 1×10^13 vp [168]. - 66.6% of patients receiving huCART-meso after VCN-01 showed tumor shrinkage, indicating a potential benefit of the combination therapy [167]. - The study of VCN-01 in patients with high-grade brain tumors aims to confirm the presence of the treatment in resected specimens, potentially paving the way for larger trials [170]. - VCN-01 showed sustained blood levels and increased serum hyaluronidase levels for over six weeks, indicating biological activity in patients [168]. - The clinical trial of huCART-meso cells in combination with VCN-01 demonstrated safety consistent with expectations from monotherapy studies [167]. - VCN-01 combined with liposomal irinotecan showed significant tumor growth inhibition in pancreatic cancer models [189][195]. - VCN-11, a next-generation oncolytic adenovirus, exhibited 450 times more cytotoxicity in tumor cells compared to normal cells [191]. Financial Performance - The company implemented a workforce reduction of approximately 32%, or seven employees, to focus resources on business development and clinical trial planning, expecting to save approximately $1.8 million annually [125]. - The company raised approximately $4.4 million from the exercise of existing warrants, with net proceeds expected to be used for working capital [127]. - The company plans to extend its cash runway into the first quarter of 2027 through cost reductions and capital raised from the ATM Sales Agreement [125]. - General and administrative expenses decreased by 18% to $1.9 million for the three months ended September 30, 2025, from $2.3 million for the same period in 2024 [209]. - Research and development expenses decreased by 7% to $2.6 million for the three months ended September 30, 2025, from approximately $2.7 million for the same period in 2024 [210]. - Total research and development expenses for the nine months ended September 30, 2025, were $7.5 million, a decrease of 18% from approximately $9.1 million for the same period in 2024 [217]. - The net loss for the three months ended September 30, 2025, was $4.4 million, or ($0.45) per common share, compared to a net loss of $7.7 million, or ($6.81) per common share for the same period in 2024 [215]. - The net loss attributable to common stockholders for the nine months ended September 30, 2025, was approximately $21.7 million, or ($3.38) per share, compared to a net loss of approximately $21.2 million, or ($24.47) per share for the same period in 2024 [222]. - As of September 30, 2025, the accumulated deficit was $356.7 million, with expectations of continued losses due to reliance on successful phase 3 clinical trials and FDA approvals [223]. - Cash and cash equivalents totaled $7.5 million as of September 30, 2025, a decrease of $4.1 million from December 31, 2024, but increased to $15.5 million in early November 2025 due to net proceeds from sales [224]. - Cash used in operating activities was $13.8 million for the nine months ended September 30, 2025, compared to $12.2 million for the same period in 2024, primarily for the development of VCN-01 [235]. - Cash provided by financing activities for the nine months ended September 30, 2025, included $1.8 million from research and development tax credits and $6.7 million from the sale of Common Stock [237]. - The company has an obligation to pay up to $70.2 million in additional consideration under the VCN Purchase Agreement, with $6.8 million paid to date [229]. - Future clinical trials are expected to require larger cash expenditures, and the company currently lacks committed sources of financing for these trials [227]. - The company anticipates needing additional funding to continue the development of product candidates and to maintain operations beyond early 2027 [232]. - There is substantial doubt about the company's ability to continue as a going concern without additional capital or strategic actions [225]. Research and Development - The company is exploring value creation options for its previous GI disease assets, SYN-004 and SYN-020, including out-licensing or partnering [123]. - The Phase 1b/2a clinical trial of SYN-004 (ribaxamase) aims to evaluate safety and tolerability in up to 36 adult allogeneic hematopoietic cell transplant (HCT) recipients [177]. - Positive outcomes from the Data and Safety Monitoring Committee review allowed the study to proceed to the second cohort, which involves administering SYN-004 with piperacillin/tazobactam [178]. - The SYN-004 program targets prevention of antibiotic-mediated microbiome damage, potentially reducing the incidence of Clostridioides difficile infection (CDI) and acute graft-versus-host disease (aGVHD) [173]. - The company is actively maintaining and building its patent portfolio to support its gastrointestinal and microbiome-focused pipeline [172]. - SYN-004 (ribaxamase) Phase 1b/2a trial safety and pharmacokinetic data presented at major conferences in 2023 [179][180]. - SYN-020 production cost anticipated to be a few hundred dollars per gram, significantly lower than the current market price of $10,000 per gram [182]. - SYN-020 demonstrated a favorable safety profile in Phase 1 studies, with no serious adverse events reported [185]. - The company is exploring strategic opportunities for SYN-004 and SYN-020 assets, including out-licensing or partnerships [188]. - Enrollment for the third cohort of the SYN-004 trial is contingent on obtaining grant funding or finding a partner [180]. - Research and development expenses directly related to VCN-01 were $1.4 million for the three months ended September 30, 2024, compared to $1.37 million for the same period in 2025 [212]. - Total direct research and development costs for the nine months ended September 30, 2025, were $4.89 million, down from $5.77 million for the same period in 2024 [218]. - The fair value of in-process R&D was written down from $19.8 million to $18.6 million, resulting in a $1.3 million impairment charge during the nine months ended September 30, 2024 [220]. - The charge related to stock-based compensation expense was $269,000 for the nine months ended September 30, 2025, compared to $335,000 for the same period in 2024 [216]. - Contingent consideration liabilities increased by $9.2 million due to the achievement of primary survival and safety endpoints in the VIRAGE Phase 2b clinical trial of VCN-01 [216]. - Theriva Biologics holds over 135 U.S. and foreign patents, supporting its various programs [197]. - SYN-004 and SYN-020 programs are backed by strong intellectual property, with patent terms extending to at least 2035 and 2038-2040 respectively [198][199]. - THERICEL program aims to enhance the efficiency and reduce the cost of VCN-01 manufacturing for clinical trials [194]. Corporate Governance - The company filed a prospectus supplement to offer and sell up to $2,534,352 of common stock, with sales made through an at-the-market offering [124]. - The Board approved an amendment to the 2020 Stock Incentive Plan, increasing the number of shares available for grant from 2,500,000 to 4,500,000 [128]. - The company does not recognize Right of Use (ROU) assets or lease liabilities for short-term leases with original terms of 12 months or less [240]. - As of September 30, 2025, the company did not have any material finance leases [240]. - ROU assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term [239].

Financial Performance - Cash and cash equivalents totaled $7.5 million as of September 30, 2025, down from $11.6 million as of December 31, 2024; following a capital raise, cash increased to $15.5 million as of November 10, 2025, extending the cash runway into Q1 2027[1][10] - Other income for Q3 2025 was $79,000, down from $161,000 in Q3 2024, primarily due to a decrease in interest income[9] - Net loss for the three months ended September 30, 2025, was $4,361,000 compared to a net loss of $7,726,000 for the same period in 2024, showing an improvement of about 43%[20] - The company reported a total comprehensive loss of $19,802,000 for the nine months ended September 30, 2025, compared to $21,126,000 in 2024, indicating a decrease of approximately 6%[20] Expenses - General and administrative expenses decreased by 18% to $1.9 million for Q3 2025, down from $2.3 million in Q3 2024, primarily due to reduced compensation costs[7] - Research and development expenses decreased by 7% to $2.6 million for Q3 2025, compared to approximately $2.7 million in Q3 2024, attributed to lower clinical trial expenses related to the completion of the VIRAGE Phase 2b trial[8] - Research and development expenses for the nine months ended September 30, 2025, were $7,472,000, down from $9,145,000 in 2024, a reduction of approximately 18%[20] - General and administrative expenses decreased from $5,702,000 for the nine months ended September 30, 2024, to $14,516,000 in 2025, reflecting a significant increase of about 154%[20] - The company expects a decrease in general and administrative expenses due to a workforce reduction implemented on September 30, 2025[7] Clinical Trials and Research - The VIRAGE Phase 2b trial demonstrated improved overall survival (OS) and progression-free survival (PFS) for metastatic pancreatic ductal adenocarcinoma (PDAC) patients receiving VCN-01 with standard-of-care chemotherapy compared to those receiving chemotherapy alone[6][4] - VCN-01 was administered to 142 patients in various clinical trials, including those for PDAC, with a focus on enhancing tumor immunogenicity and improving chemotherapy access[11] - Preclinical data for VCN-12 showed increased cell killing compared to VCN-01 in various cancer cell models, indicating potential for enhanced therapeutic efficacy[6] - The company plans to discuss a potential Phase 3 clinical trial protocol for VCN-01 with regulators in Europe and the United States in the first half of 2026[2][6] - Additional funding will be required to initiate new VCN-01 clinical trials following the completion of the VIRAGE Phase 2b trial[10] - Additional funding will be required to initiate new VCN-01 clinical trials, highlighting the need for ongoing financial support[15] Assets and Liabilities - Total current assets decreased from $16,281,000 on December 31, 2024, to $9,903,000 on September 30, 2025, a decline of approximately 39%[18] - Cash and cash equivalents dropped from $11,609,000 to $7,528,000, representing a decrease of about 35%[18] - Total liabilities increased from $16,285,000 at the end of 2024 to $24,098,000, marking a rise of approximately 48%[18] Strategic Positioning - The company is positioned to advance its regulatory and clinical strategies and explore potential partnerships for its innovative assets[15] - Current cash funding operations are projected to last into the first quarter of 2027, including overhead costs and the closeout of the VIRAGE Phase 2b clinical trial[15]